J.P. Morgan upgrades Biogen to 'overweight', shares rise
BUZZ-J.P. Morgan upgrades Biogen to 'overweight', shares rise ** Shares of drug maker Biogen BIIB.O rise nearly 2% to $230.35 premarket
** J.P. Morgan upgrades stock rating to "overweight" from "neutral"; raises PT to $300 from $210, which represents ~33% upside to the stock's last close on Friday
** Brokerage sees several key 2027 catalysts, including felzartamab for antibody-mediated rejection (AMR) in organ transplants, a potential $2 billion-plus market opportunity
** "We see BIIB as one of the more attractive names to own heading into 2027 as the company evolves beyond just a Leqembi story", (the Alzheimer's disease treatment)
** 38 analysts rate stock "buy" on average; median PT is $242 - data compiled by LSEG
** Up to last day's close, the stock had risen 28.25% YTD
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com ; X, formerly Twitter: @AkritiShahh))